Introduction {#s0001}
============

Cessation of antiretrovirals raises concerns about the potential for the development of drug-resistant viral strains, particularly for non-nucleoside reverse transcriptase inhibitors (NNRTIs). Non-nucleoside reverse transcriptase inhibitors, such as efavirenz (EFV), have long half-lives and a low barrier to the development of drug resistance. When used in combination with other classes of drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), staggered discontinuation using a 4--7-day 'tail' of the NRTI backbone when stopping NNRTI-based antiretroviral treatment (ART) is advised.^[@CIT0001]^ This is believed to mitigate the unintended period of monotherapy with NNRTIs that ensues because of the long half-life of most drugs in this class, thus reducing the risk of developing drug resistance.^[@CIT0002],[@CIT0003]^ There are, however, very limited data to directly support this recommendation for a tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) 'tail': following cessation of EFV. Of note, pharmacokinetic variability (linked genetic factor -- CYP2B6) in EFV metabolism between individuals has been observed, and EFV levels may be higher in persons of African descent.^[@CIT0004]^ These higher drug levels may also impact risk of drug resistance when stopping EFV-based ART.

Prior to 2015, both the World Health Organization (WHO) and the Botswana programme for the prevention of mother-to-child transmission (PMTCT) recommended that pregnant women living with HIV with a CD4 cell count \> 350 cells/mm^3^ without a WHO stage 3 or 4 illness take three-drug ART in pregnancy, but discontinue the ART postpartum or upon breastfeeding cessation (option B). Although both WHO and Botswana subsequently modified guidelines to recommend lifelong ART regardless of CD4 cell count or disease stage (option B+), the prior guidance for pregnant women, as well as the inconsistent application of an NRTI tail at the time of EFV cessation, offers an opportunity to evaluate the development of resistance and the performance of a TDF/FTC tail among women stopping an EFV/TDF/FTC regimen. Because this ART regimen remains widely used throughout the world, the natural experiment afforded by prior PMTCT guidelines is applicable to our understanding of the risk of cessation of NNRTI-based regimens generally.

Methods {#s0002}
=======

Study population {#s20003}
----------------

Between April 2014 and May 2015, we enrolled a subset of pregnant women living with HIV participating in a trial of infant cotrimoxazole prophylaxis in Botswana (the 'Mpepu' study) into this resistance sub-study. Mpepu was a double-blinded randomised controlled trial designed to assess the efficacy and safety of infant cotrimoxazole prophylaxis versus placebo used daily from as early as 14 days of life through 15 months among HIV-exposed uninfected infants in Botswana.^[@CIT0005]^

Women were eligible for this sub-study of drug resistance following cessation of EFV/FTC/TDF if they were living with HIV, had pre-treatment CD4 \> 350 cells/mm^3^ without evidence of WHO stage 3 or 4 disease, initiated EFV/FTC/TDF in pregnancy and stopped ART postpartum according to Botswana guidelines at the time (at 4--6 weeks postpartum if formula feeding, or 6 weeks after weaning if breastfeeding). Per Botswana national HIV treatment guidelines, a 7-day tail of TDF/FTC after cessation of EFV was recommended. However, decisions regarding receipt and cessation of maternal ART occurred at government clinics (rather than study clinics), and the 7-day tail was inconsistently applied at the time of ART cessation.

Data collection and laboratory testing {#s20004}
--------------------------------------

Women eligible to participate in this sub-study were identified in the Mpepu study and scheduled for a clinic visit 4--6 weeks after ART cessation. Interested and eligible women consented to participate in the study and provided data (from self-report and medical records) on PMTCT regimen received; dates on which ART and individual antiretrovirals were started and stopped as well as provided blood specimens for drug resistance and HIV-1 RNA testing. HIV RNA results at the point of enrolment into the Mpepu study, and documented nadir CD4 counts, were retrieved and served as baseline values.

Prior to drug resistance testing, we first determined HIV-1 RNA viral load levels with the Abbott m2000sp/rt machine (limit of detection 40 copies/mL). Where HIV-1 RNA was detected, it was extracted using an automated validated technique.^[@CIT0006]^ We then performed reverse transcription using in-house one-step RT-PCR technique.^[@CIT0007]^ Polymerase chain reaction (PCR) products were then purified^[@CIT0008]^ and sequenced.^[@CIT0009]^ Consensus sequences were generated, and the Stanford HIV Drug Resistance Database was used to identify all drug resistance mutations in the protease and reverse transcriptase coding regions.

Statistical methods {#s20005}
-------------------

Statistical Package for Social Sciences (SPSS) version 25 was used to perform statistical analyses, which were generally descriptive in nature; a two-sided Fisher's exact test was used to evaluate for differences in the proportion of drug resistance by the approach to ART cessation, either with a 7-day TDF/FTC tail or with abrupt cessation of all three drugs. The small number of women with drug resistance mutations precluded more detailed analysis of predictors of drug resistance.

Ethical onsiderations {#s20006}
---------------------

The Botswana Health Research Development Committee and the Office of Human Research Administration at Harvard T. H. Chan School of Public Health approved this drug resistance sub-study (HRDC 00732 and IRB13-2772), and women provided written informed consent for participation.

Results {#s0007}
=======

Baseline characteristics {#s20008}
------------------------

Ninety women enrolled, 74 of whom discontinued EFV/FTC/TDF postpartum and had samples collected for genetic resistance testing and are included in this analysis. Sixteen of 90 women not included in this analysis had CD4 \< 350 cell/mm^3^ post-delivery and had to continue ART for their own health per Botswana national protocol at the time. The median time from cessation of EFV (whether or not a tail period occurred) to time sample was collected for resistance testing was 5 weeks (range: 3--13 weeks). Median age at enrolment was 29 years (range: 20--45) with median nadir CD4 count of 571 cells/mm^3^ (range: 361--1236). Forty-seven (64%) women had no previous exposure to antiretrovirals, 25 (34%) reported previous exposure to antiretrovirals for PMTCT purposes in a prior pregnancy and 2 (2%) were previously exposed to EFV/FTC/TDF but stopped prior to conception and then re-started EFV/FTC/TDF as three-drug prophylaxis for the index pregnancy. Thirty-two (43%) stopped ART with the recommended 1-week tail of TDF/FTC after cessation of EFV and 42 (57%) stopped all treatment at once. Of 70 women with viral load results at enrolment into the Mpepu study, 58 (83%) had HIV-1 RNA \< 40 copies/mL. At 4--6 weeks post-EFV/FTC/TDF cessation, 44 (62%) of 71 women with viral load result had HIV-1 RNA \< 40 copies/mL. Thirty-three (47%) women had HIV-1 RNA \< 40 copies/mL at delivery and at the time of sample draw for genotyping (post-ARV cessation).

Mutations {#s20009}
---------

Thirty-five (47%) of 74 samples were successfully sequenced, with 4 (11%) of 35 having a major drug resistance mutation: 2 with K103N and 2 with V106M ([Table 1](#T0001){ref-type="table"}). All four resistance mutations occurred among women who did not receive a TDF/FTC tail (4/42, 10%), whereas no mutations occurred among 18 genotyped women who had received a TDF/FTC tail (*p* = 0.053). Eighteen (58%) of the 31 women who had a genotype result and no drug resistance mutation took a TDF/FTC tail. Of 39 samples that could not be sequenced, 37 (95%) had HIV-1 RNA \< 40 copies/mL in the sample being tested.

###### 

Characteristics of women with successful sequencing post-antiretroviral treatment cessation.

  Age (years)   Prior use of ART for own health   Prior use of ART for PMTCT              Received TDF/FTC tail   Duration of ART use (weeks)   Nadir CD4 (cell/UI)   Baseline VL (copies/mL)   Post ART cessation VL (copies/mL)      Mutation
  ------------- --------------------------------- --------------------------------------- ----------------------- ----------------------------- --------------------- ------------------------- -------------------------------------- ----------
  27            No                                Yes                                     Yes                     31.6                          518                   \< 40                     42 166                                 E138A
  27            No                                No                                      Yes                     38.4                          570                   \< 40                     \< 40                                  E138A
  23            No                                No                                      Yes                     40.7                          710                   \< 40                     13 120                                 K103N
  25            No                                No                                      Yes                     10.1                          572                   \< 40                     1719                                   K103N
  35            No                                No                                      No                      54.5                          772                   \< 40                     18 259                                 None
  40            No                                Yes                                     Yes                     31.2                          442                   \< 40                     2658                                   None
  36            No                                Yes                                     No                      20.4                          963                   \< 40                     \< 40                                  None
  25            No                                No                                      No                      20.2                          611                   \< 40                     857                                    None
  35            No                                No                                      No                      11.4                          430                   \< 40                     \-                                     None
  25            No                                No                                      Yes                     15.8                          575                   \< 40                     33 906                                 None
  24            No                                No                                      Yes                     25.2                          496                   \< 40                     5688                                   None
  26            No                                Yes                                     No                      25.6                          460                   \< 40                     2342                                   None
  27            No                                Yes                                     Yes                     14.0                          908                   \< 40                     1805                                   None
  29            No                                No                                      Yes                     23.1                          436                   58                        379                                    None
  42            No                                No                                      Yes                     27.8                          533                   \< 40                     \< 40                                  None
  40            No                                No                                      No                      13.5                          361                   52                        250                                    None
  33            Yes                               No                                      Yes                     10.8                          796                   \< 40                     \< 40                                  None
  30            No                                No                                      No                      21.1                          616                   \-                        9764                                   None
  26            No                                No                                      No                      24.9                          1037                  \< 40                     554                                    None
  27            No                                No                                      Yes                     16.1                          601                   \< 40                     3648                                   None
  40            No                                No                                      Yes                     24.6                          363                   \< 40                     33 432                                 None
  27            No                                No                                      No                      81.6                          673                   \< 40                     196 735                                None
  24            No                                No                                      Yes                     39.2                          800                   \< 40                     \< 40                                  None
  31            Yes                               No                                      No                      36.7                          1236                  \< 40                     \-                                     None
  31            No                                Yes                                     Yes                     11.0                          589                   125                       \< 40                                  None
  29            No                                No                                      No                      18.5                          715                   \< 40                     2261                                   None
  26            No                                Yes                                     No                      96.2                          612                   \<40                      \< 40                                  None
  41            No                                No                                      No                      82.1                          840                   \-                        2229                                   None
  35            No                                Yes                                     No                      45.8                          960                   \< 40                     4536                                   None
  40            No                                Yes                                     No                      26.8                          679                   \< 40                     972                                    None
  28            No                                No                                      No                      21.9                          436                   \< 40                     40 709                                 None
  26            No                                No                                      No                      23.2                          397                   \< 40                     309                                    None
  24            No                                No                                      No                      26.5                          468                   52                        \< 40                                  None
  20            No                                No                                      Yes                     22.4                          384                   45                        68[†](#TFN0001){ref-type="table-fn"}   V106M
  33            No                                Yes[‡](#TFN0002){ref-type="table-fn"}   Yes                     23.8                          468                   \< 40                     145 392                                V106M

ART, antiretroviral treatment; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; VL, viral load.

, Genotypes were performed independent of the knowledge of the participants' viral load; therefore, verification of the viral load on individual plasma sample was not performed.

, Previous exposure to zidovudine for prevention of mother-to-child transmission (PMTCT).

Discussion {#s0010}
==========

A small proportion of women stopping EFV/FTC/TDF had a major NNRTI resistance mutation detected in plasma taken a little more than a month after stopping treatment. Among women receiving a 7-day tail of TDF/FTC after stopping EFV where genetic resistance testing was able to be performed, none had detectable mutations. Our findings thus support the recommended staggered discontinuation of antiretrovirals when an EFV/FTC/TDF regimen is being stopped. Our data support prior studies that evaluated the use of an NRTI tail when discontinuing EFV-based ART.

Our observation of prolonged viral suppression \< 40 copies/mL for a median of 5 weeks in 62% of women post-ART cessation was similar to findings from other studies which have demonstrated that it is not unusual for viral suppression to persist for weeks after stopping ART.^[@CIT0010]^ We believe this could be because of low pre-ART viral loads in our population (because of women with less advanced disease starting ART in pregnancy).

Our study had several limitations. Firstly, our results are based on a small number of observations making generalisability challenging. Secondly, we did not report on minor drug resistance variants and, finally, more than half (63%) of women tested at a median time of 5 weeks from EFV cessation were still virally suppressed, which may suggest that we might have tested for resistance strain development early. Thirdly, we could not determine why the 7-day tail was inconsistently applied at the time of ART cessation and could therefore have missed evaluating possible confounders related to this factor.

Conclusion {#s0011}
==========

Although guidelines no longer recommend discontinuation of ART after pregnancy, our study has general applicability for those requiring permanent or temporary treatment discontinuation when receiving an EFV-based regimen, informing the risk of mutation emergence in the setting of abrupt three-drug discontinuation versus discontinuing with a TDF/FTC tail. Furthermore, despite the shift to the use of newer drugs such as dolutegravir for which there is less concern about the emergence of resistance than with NNRTIs, our data are relevant to millions of individuals still on EFV-based ART (and are of particular clinical importance in regions that have access to only a limited number of antiretroviral drugs and that are also generally unable to routinely assess for drug resistance mutations before initiating a new ART regimen).

Based upon our results, we conclude that an TDF/FTC tail may help prevent selection of major NNRTI drug resistance mutations that can occur with the abrupt discontinuation of an EFV/FTC/TDF ART regimen.
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